Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 5/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28800774 | 0.98 | KCNN4 (0.41) | KCNN4MAPK1KIF11ALDH1A1TAAR1 | |
| SCHEMBL28528178 | 0.89 | KCNN4 (0.39) | KCNN4MAPK1KIF11ALDH1A1TAAR1 | |
| SCHEMBL474157 | 0.87 | KCNN4 (0.38) | KCNN4MAPK1KIF11ALDH1A1TAAR1 | |
| SCHEMBL11783048 | 0.83 | LTA4H (0.38) | KCNN4KIF11LTA4HTSHR | |
| SCHEMBL6421037 | 0.83 | KIF11 (0.43) | KCNN4MAPK1KIF11ALDH1A1TAAR1 | |
| SCHEMBL6155774 | 0.81 | KCNN4 (0.44) | KCNN4MAPK1KIF11ALDH1A1TAAR1 | |
| SCHEMBL11156805 | 0.80 | KCNN4 (0.43) | KCNN4MAPK1KIF11ALDH1A1TAAR1 | |
| SCHEMBL7053535 | 0.80 | KCNN4 (0.43) | KCNN4MAPK1KIF11ALDH1A1TAAR1 | |
| SCHEMBL2350021 | 0.80 | KIF11 (0.56) | KCNN4MAPK1KIF11ALDH1A1TAAR1 | |
| SCHEMBL9576889 | 0.79 | KCNN4 (0.35) | KCNN4MAPK1KIF11ALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 536 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026097873-A1 | HALOGENATED INDOLINONE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF, HALOGENATED INDOLINONE DERIVATIVE AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 广州湾区生物医药研究院 | 2026-05-15 | — | — | WO | claimed |
| CN-114867888-B | Method for depositing film | 弗萨姆材料美国有限责任公司 | 2025-05-30 | — | — | CN | claimed |
| CN-119841763-A | Halogenated indolone compound, preparation method and application thereof, halogenated indolone derivative and application thereof, pharmaceutical composition and application thereof | 广州湾区生物医药研究院 | 2025-04-18 | — | — | CN | claimed |
| CN-119613414-A | Non-azolanet Process for the preparation of tam | 上海皓元医药股份有限公司 | 2025-03-14 | — | — | CN | claimed |
| EP-4065746-B1 | METHOD FOR DEPOSITING A FILM | VERSUM MAT US LLC (US) | 2024-09-04 | — | — | EP | claimed |
| US-12059467-B2 | Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same | ANHUI UNIVERSITY (CN) | 2024-08-13 | — | — | US | claimed |
| EP-3925948-B1 | INTERMEDIATE OF ERIBULIN, SYNTHESIS METHOD THEREFOR AND USE THEREOF | BEIJING TIENYI LUFU PHARMATECH CO LTD (CN) | 2024-08-07 | — | — | EP | claimed |
| US-20240108728-A1 | IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME | ANHUI UNIVERSITY (CN) | 2024-04-04 | — | — | US | claimed |
| CN-117486966-A | Method for synthesizing brassinolide | 山东成武泽大泛科化工有限公司 | 2024-02-02 | — | — | CN | claimed |
| WO-2023221320-A1 | IMPROVED LOW-TOXICITY AND HIGHLY EFFICIENT PHARMACEUTICAL EXCIPIENT OF ORTHOESTER MIXTURE, METHOD FOR PREPARING SAME, AND LOCAL SUSTAINED-RELEASE PREPARATION COMPRISING SAME | 安徽大学 | 2023-11-23 | — | — | WO | claimed |
| CN-112592307-A | Preparation method of nintedanib intermediate | 上海翰森生物医药科技有限公司 | 2021-04-02 | — | — | CN | claimed |
| CN-112147260-A | Method for simultaneously detecting 4 secondary metabolites in stylosanthes guianensis by UPLC method | 中国热带农业科学院分析测试中心 | 2020-12-29 | — | — | CN | claimed |
| CN-111848369-A | Eribulin intermediate, and synthesis method and application thereof | 北京天一绿甫医药科技有限公司 | 2020-10-30 | — | — | CN | claimed |
| CN-111848490-A | Preparation method of high-purity ethanesulfonic acid nintedanib | 江西国药有限责任公司 | 2020-10-30 | — | — | CN | claimed |
| WO-2020216034-A1 | INTERMEDIATE OF ERIBULIN, SYNTHESIS METHOD THEREFOR AND USE THEREOF | 北京天一绿甫医药科技有限公司 | 2020-10-29 | — | — | WO | claimed |
| CN-111662223-A | Process for producing indolinone derivative and intermediate thereof | 四川科伦药物研究院有限公司 | 2020-09-15 | — | — | CN | claimed |
| US-20170218162-A1 | RECYCLING PROCESS | WORN AGAIN TECHNOLOGIES LIMITED (GB) | 2017-08-03 | — | — | US | claimed |
| EP-3172267-A1 | RECYCLING PROCESS | Worn Again Footwear And Accessories Limited (GB) | 2017-05-31 | — | — | EP | claimed |
| WO-2016012755-A1 | RECYCLING PROCESS | WORN AGAIN FOOTWEAR AND ACCESSORIES LIMITED (GB) | 2016-01-28 | — | — | WO | claimed |
| US-4252738-A | 1,2-Halohydrincarboxylic acid esters and a process for their preparation | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108728-A1 | IMPROVED LOW-TOXICITY AND HIGH-EFFICIENCY ORTHOESTER MIXTURE PHARMACEUTICAL ADJUVANT, PREPARATION METHOD THEREOF, AND TOPICAL SUSTAINED RELEASE DRUG DELIVERY FORMULATION INCLUDING SAME | TLR7, PON1, MYD88 | KCNN4 3422/4885MAPK1 1473/4885KIF11 258/4885 |
| US-12059467-B2 | Low-toxicity and high-efficiency orthoester mixture pharmaceutical adjuvant, preparation method thereof, and topical sustained release drug delivery formulation including same | TLR7, PON1, MYD88 | KCNN4 3339/4885MAPK1 1397/4885KIF11 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.